{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:01:12Z","timestamp":1792119672367,"version":"4.4.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T00:00:00Z","timestamp":1617840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T00:00:00Z","timestamp":1617840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Astellas Pharma, Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s10637-021-01112-7","type":"journal-article","created":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T07:03:49Z","timestamp":1617865429000},"page":"1348-1356","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancer"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8123-4065","authenticated-orcid":false,"given":"Filip","family":"Janku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"LoRusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron S.","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Nanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Spira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Melhem-Bertrandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Sugg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard A.","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,8]]},"reference":[{"issue":"6","key":"1112_CR1","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.bbabio.2011.08.010","volume":"1817","author":"M Mimaki","year":"2012","unstructured":"Mimaki M, Wang X, McKenzie M, Thorburn DR, Ryan MT (2012) Understanding mitochondrial complex I assembly in health and disease. Biochim Biophys Acta 1817(6):851\u2013862. https:\/\/doi.org\/10.1016\/j.bbabio.2011.08.010","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"1112_CR2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1042\/BJ20140620","volume":"462","author":"HR Bridges","year":"2014","unstructured":"Bridges HR, Jones AJ, Pollak MN, Hirst J (2014) Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochem J 462(3):475\u2013487. https:\/\/doi.org\/10.1042\/BJ20140620","journal-title":"Biochem J"},{"issue":"9","key":"1112_CR3","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1158\/2159-8290.CD-12-0263","volume":"2","author":"MN Pollak","year":"2012","unstructured":"Pollak MN (2012) Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov 2(9):778\u2013790. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0263","journal-title":"Cancer Discov"},{"key":"1112_CR4","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1042\/bj3480607","volume":"3","author":"MR Owen","year":"2000","unstructured":"Owen MR, Doran E, Halestrap AP (2000) Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 348 Pt 3:607\u2013614","journal-title":"Biochem J 348 Pt"},{"issue":"18","key":"1112_CR5","doi-asserted-by":"publisher","first-page":"5639","DOI":"10.1158\/1078-0432.CCR-17-1115","volume":"23","author":"NV Rajeshkumar","year":"2017","unstructured":"Rajeshkumar NV, Yabuuchi S, Pai SG, De Oliveira E, Kamphorst JJ, Rabinowitz JD, Tejero H, Al-Shahrour F, Hidalgo M, Maitra A, Dang CV (2017) Treatment of pancreatic cancer patient-derived xenograft panel with metabolic inhibitors reveals efficacy of phenformin. Clin Cancer Res 23(18):5639\u20135647. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-1115","journal-title":"Clin Cancer Res"},{"issue":"7503","key":"1112_CR6","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1136\/bmj.38415.708634.F7","volume":"330","author":"JM Evans","year":"2005","unstructured":"Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330(7503):1304\u20131305. https:\/\/doi.org\/10.1136\/bmj.38415.708634.F7","journal-title":"BMJ"},{"issue":"1","key":"1112_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s40478-019-0712-8","volume":"7","author":"T Sundstrom","year":"2019","unstructured":"Sundstrom T, Prestegarden L, Azuaje F, Aasen SN, Rosland GV, Varughese JK, Bahador M, Bernatz S, Braun Y, Harter PN, Skaftnesmo KO, Ingham ES, Mahakian LM, Tam S, Tepper CG, Petersen K, Ferrara KW, Tronstad KJ, Lund-Johansen M, Beschorner R, Bjerkvig R, Thorsen F (2019) Inhibition of mitochondrial respiration prevents BRAF-mutant melanoma brain metastasis. Acta Neuropathol Commun 7(1):55. https:\/\/doi.org\/10.1186\/s40478-019-0712-8","journal-title":"Acta Neuropathol Commun"},{"issue":"42","key":"1112_CR8","doi-asserted-by":"publisher","first-page":"10756","DOI":"10.1073\/pnas.1808945115","volume":"115","author":"M Benej","year":"2018","unstructured":"Benej M, Hong X, Vibhute S, Scott S, Wu J, Graves E, Le QT, Koong AC, Giaccia AJ, Yu B, Chen CS, Papandreou I, Denko NC (2018) Papaverine and its derivatives radiosensitize solid tumors by inhibiting mitochondrial metabolism. Proc Natl Acad Sci U S A 115(42):10756\u201310761. https:\/\/doi.org\/10.1073\/pnas.1808945115","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"1112_CR9","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1158\/1535-7163.MCT-12-1226-T","volume":"12","author":"M Cerezo","year":"2013","unstructured":"Cerezo M, Tichet M, Abbe P, Ohanna M, Lehraiki A, Rouaud F, Allegra M, Giacchero D, Bahadoran P, Bertolotto C, Tartare-Deckert S, Ballotti R, Rocchi S (2013) Metformin blocks melanoma invasion and metastasis development in AMPK\/p53-dependent manner. Mol Cancer Ther 12(8):1605\u20131615. https:\/\/doi.org\/10.1158\/1535-7163.MCT-12-1226-T","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"1112_CR10","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.mce.2012.06.016","volume":"366","author":"KA Brown","year":"2013","unstructured":"Brown KA, Samarajeewa NU, Simpson ER (2013) Endocrine-related cancers and the role of AMPK. Mol Cell Endocrinol 366(2):170\u2013179. https:\/\/doi.org\/10.1016\/j.mce.2012.06.016","journal-title":"Mol Cell Endocrinol"},{"issue":"7","key":"1112_CR11","doi-asserted-by":"publisher","first-page":"e245","DOI":"10.1038\/emm.2016.81","volume":"48","author":"SM Jeon","year":"2016","unstructured":"Jeon SM (2016) Regulation and function of AMPK in physiology and diseases. Exp Mol Med 48(7):e245. https:\/\/doi.org\/10.1038\/emm.2016.81","journal-title":"Exp Mol Med"},{"issue":"2","key":"1112_CR12","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ygyno.2008.04.008","volume":"110","author":"WH Gotlieb","year":"2008","unstructured":"Gotlieb WH, Saumet J, Beauchamp MC, Gu J, Lau S, Pollak MN, Bruchim I (2008) In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol 110(2):246\u2013250. https:\/\/doi.org\/10.1016\/j.ygyno.2008.04.008","journal-title":"Gynecol Oncol"},{"issue":"38","key":"1112_CR13","doi-asserted-by":"publisher","first-page":"24980","DOI":"10.18632\/oncotarget.25166","volume":"9","author":"HV Vangapandu","year":"2018","unstructured":"Vangapandu HV, Alston B, Morse J, Ayres ML, Wierda WG, Keating MJ, Marszalek JR, Gandhi V (2018) Biological and metabolic effects of IACS-010759, an OxPhos inhibitor, on chronic lymphocytic leukemia cells. Oncotarget 9(38):24980\u201324991. https:\/\/doi.org\/10.18632\/oncotarget.25166","journal-title":"Oncotarget"},{"issue":"15_suppl","key":"1112_CR14","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1200\/JCO.2019.37.15_suppl.3014","volume":"37","author":"TA Yap","year":"2019","unstructured":"Yap TA, Ahnert JR, Piha-Paul SA, Fu S, Janku F, Karp DD, Naing A, Dumbrava EEI, Pant S, Subbiah V, Tsimberidou AM, Hong DS, Rose KM, Xu Q, Vellano CP, Mahendra M, Jones P, Di Francesco ME, Marszalek JR, Meric-Bernstam F (2019) Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumors. J Clin Oncol 37(15_suppl):3014","journal-title":"J Clin Oncol"},{"key":"1112_CR15","doi-asserted-by":"crossref","unstructured":"Rha SY, Beom SHB, Kim GM, Shin YG, Yim D-S, Kim HS, Chang JH, Cheong J-H, Lee YW, Chong YS, O\u2019Neill V, Yoo SH, Janku, F (2019) Phase I study of an oxidative phosphorylation inhibitor IM156 in patients with advaned solid tumors. In: American Associaiton for Cancer Research, Atlanta, p CT021\/016","DOI":"10.1158\/1538-7445.AM2019-CT021"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01112-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-021-01112-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01112-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:09:06Z","timestamp":1678493346000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-021-01112-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,8]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1112"],"URL":"https:\/\/doi.org\/10.1007\/s10637-021-01112-7","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,8]]},"assertion":[{"value":"30 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr Filip Janku reports grants from Novartis, Genentech, BioMed Valley Discoveries, Plexxikon, Deciphera, Piqur, Symphogen, Bayer, FujiFilm Corporation, Astex, Asana, Astellas, Agios, Proximagen, and Bristol-Myers Squibb; and other support from Deciphera, IFM Therapeutics, Synlogic, Guardant Health, Ideaya, PureTech Health, Jazz Pharmaceuticals, Trovagene, Immunomet, Primmune Therapeutics, and Sotio, outside the submitted work.Dr Patricia LoRusso reports honorarium from advisory boards from AbbVie, Agios, GenMab, Genentech, CytomX, Takeda, Cyrexa, Agenus, IQVIA, TRIGR, Pfizer, I-MAB, ImmunoMet, Black Diamnod, Glaxo-Smith Kline, QED Therapeutics, AstraZeneca, EMD Serono, Shattuck, Astellas, Salarius, Silverback, MacroGenics; and has been a consultant for Five Prime, Halozyme, Roche-Genentech, SOTIO, and Tyme.Dr Aaron Mansfield has no direct conflicts, but reports research support from Bristol-Meyers Squibb, Novartis, and Verily, remuneration to his institution for participation on advisory boards for AbbVie, Astra Zeneca, BMS, and Genentech, and is a non-remunerated director of the Mesothelioma Applied Research Foundation. Dr Rita Nanda reports personal fees from Aduro, grants and personal fees from AstraZeneca, personal fees from Athenex, grants and personal fees from Celgene, personal fees from Daiichi Sankyo, grants and personal fees from Genentech, personal fees from Macrogenics, grants and personal fees from Merck, grants and personal fees from Novartis, grants and personal fees from Pfizer, personal fees from Puma, personal fees and other from G1 Therapeutics, other from OBI Pharma, grants from Immunomedics, grants from Odonate, and grants from Seattle Genetics, outside the submitted work. Dr Alexander Spira reports grants and non-financial support from Astellas during the conduct of the study; grants, personal fees, and non-financial support from Cytomx; grants, personal fees, and non-financial support from AstraZeneca; and non-financial support from Roche, outside the submitted work.Dr Tianli Wang has nothing to disclose. Dr Amal Melhem-Bertrandt was an employee of Astellas at the time of the study. Jennifer Sugg is an employee of Astellas and holds stock in AstraZeneca. Dr Howard A. Ball has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with Good Clinical Practice, the International Council for Harmonisation, and guidelines governing clinical study conduct and the ethical principles originating from the Declaration of Helsinki.The study was approved by the respective Institutional Review Boards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}